D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
2006 Highlights From: 42nd Annual Meeting of the American Society of Clinical Oncology Atlanta, GA, June 2006
Journal ArticleDOI
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study
Robert J. Morgan,Lucille Leong,Warren Chow,David R. Gandara,Paul Frankel,Agustin A. Garcia,Heinz-Josef Lenz,James H. Doroshow,James H. Doroshow +8 more
TL;DR: A modest response rate is observed in patients with recurrent or persistent ovarian cancer treated with the combination of bryostatin and cisplatin, and the toxicity profile, however, observed in this pt population, precludes tolerability and prevents this combination from further investigation at this dose and schedule.
Journal ArticleDOI
A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial
Barbara J. Gitlitz,Denice D. Tsao-Wei,Susan Groshen,Angela M. Davies,Marianna Koczywas,Chandra P. Belani,Athanassios Argiris,Suresh S. Ramalingam,Everett E. Vokes,Martin J. Edelman,Philip C. Hoffman,Marc S Ballas,Stephen V. Liu,David R. Gandara +13 more
TL;DR: Eribulin mesylate is well tolerated and demonstrates activity in pretreated, TS NSCLC, and is an analog of halichondrin B with a unique mechanism of microtubule binding.
Journal ArticleDOI
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Antoinette J. Wozniak,James C. Moon,Charles R. Thomas,Karen Kelly,Philip C. Mack,Laurie E. Gaspar,David Raben,Thomas J. Fitzgerald,Kishan J. Pandya,David R. Gandara +9 more
TL;DR: Bvacizumab was not safely integrated into CRT for stage III NSCLC in patients considered at high risk for hemoptysis and in lower risk patients, data are insufficient to determine safety or efficacy.
Journal ArticleDOI
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yun Yen,Dean W. Lim,Vincent Chung,Robert J. Morgan,Lucille Leong,Stephen Shibata,Stephen D. Wagman,Howard Marx,Peiguo G. Chu,Jeffrey Longmate,Heinz-Josef Lenz,Ramesh K. Ramanathan,Chandra P. Belani,David R. Gandara +13 more
TL;DR: Single agent, oxaliplatin, has produced one partial response of good duration in 36 patients, but failed to meet the a priori criterion for promise in this trial.